Crossmark

FLT PET/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab

Crossref DOI link: https://doi.org/10.1186/s40425-019-0516-1

Published Online: 2019-01-30

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Scarpelli, Matthew

Zahm, Christopher

Perlman, Scott

McNeel, Douglas G.

Jeraj, Robert

Liu, Glenn https://orcid.org/0000-0002-9819-1911
Funding

Funding for this research was provided by:

National Institutes of Health (P30 CA014520)

National Cancer Institute (R01 CA129154)

Prostate Cancer Foundation (PCF Movember Challenge Award)
More Information

Article History

Received: 6 December 2018

Accepted: 20 January 2019

First Online: 30 January 2019

Ethics approval and consent to participate

: The protocol for this study was reviewed and approved by all local (University of Wisconsin Human Subjects’ Review Board (IRB). All patients gave written informed consent for participation.

: Not applicable.

: Douglas G. McNeel has ownership interest, has received research support, and serves as consultant to Madison Vaccines, Inc. which has licensed intellectual property related to this content. None of the other authors have relevant potential conflicts of interest.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.